Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

87.02 +1.80 (+2.11%)
Streaming Delayed Price Updated: 11:17 AM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Cor

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock
Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock. 
Via InvestorPlace
1 Unstoppable Growth Stock to Buy and Hold for 10 Years
This company is finding success in fighting one of the deadliest illnesses. 
Via The Motley Fool
Cathie Wood Onto 'Next Thing' In AI After ARK's Nvidia Exit: What's On Her Radar?
 
Via Benzinga
3 High-Flying Cathie Wood Stocks That Are Up Over 50% This Year
Is it too late to buy these rebounding stocks? 
Via The Motley Fool
MarketBeat Week in Review – 5/15 - 5/19
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
Why Exact Sciences Stock Roared Higher This Week
The cancer diagnostic company's Q1 report was full of good news for shareholders. 
Via The Motley Fool
Expert Ratings for Exact Sciences
 
Via Benzinga
3 AI Stocks That Famed Investor Cathie Wood Is Betting On
Exact Sciences will look to leverage AI to revolutionize its industry. Here are some other Cathie Wood AI stocks to consider too. 
Via InvestorPlace
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
A Bull Market Is Coming: 1 Supercharged Growth Stock to Buy Hand Over Fist Before It Soars 164%, According to Wall Street
This stock has been crushed by macroeconomic headwinds but could rebound big time if analysts are right. 
Via The Motley Fool
Cathie Wood's Flagship ARK ETF Marks 5-Day Winning Streak — Outperforming Nasdaq, FAANG In May
Cathie Wood's flagship fund Ark Innovation ETF (ARCA: ARKK) marked a five-day winning streak on Wednesday for the first time since January, as a lower-than-expected U.S. 
Via Benzinga
Why Shares of Exact Sciences Rose on Wednesday
The diagnostic testing company announced strong first-quarter earnings. 
Via The Motley Fool
Exact Sciences (EXAS) Q1 2023 Earnings Call Transcript
EXAS earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Exact Sciences Guidance Beat Street View, Analyst Says Company Fires All Cylinders
Exact Sciences Corp's (NASDAQ: EXAS) Q1 revenues increased 24% Y/Y to $602 million, beating the average Wall Street esti 
Via Benzinga
Upstart, Compass, RingCentral And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones dropping around 70 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
 
Via Benzinga
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Exposures Product Safety
EXAS Stock Earnings: Exact Sciences Beats EPS, Revenue Estimates
EXAS stock posted Q1 results that include a loss per share of 42 cents and revenue that was much better than analysts expected. 
Via InvestorPlace
Exact Sciences Posts Its 11th Consecutive Sales Beat As It Targets 'The Most Preventable' Cancer
The company sells Cologuard, a test to screen for colon cancer. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
 
Via Benzinga
3 Stocks That AI Predicts Will Outperform the Market
Here are three stocks that came up when I asked the generative AI chatbot that powers Bing chat to make some AI stock recommendations 
Via InvestorPlace
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death Product Safety
The 7 Best Biotech Stocks for Personalized Medicine Investors
Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. 
Via InvestorPlace
Cathie Wood’s Next Big Bet: 3 Disruptive Innovations to Watch
These Cathie Wood stocks could deliver massive gains in the coming years as they disrupt traditional industries. 
Via InvestorPlace
What Has Cathie Wood Been Trading?
The story of Ark Invest, Wall Street veteran Cathie Wood’s lineup of actively managed, innovation-centric ETFs is well-known at this point. Ark has been defined by big bets, big wins, big losses, and... 
Via Benzinga
2 Supercharged Growth Stocks That Could Rocket 116% to 899% Higher, According to Wall Street
Find out why expectations are so high for these two innovative businesses. 
Via The Motley Fool
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire. 
Via InvestorPlace
3 Cathie Wood Stocks for Your April Must-Buy List
Cathie Wood stocks are doing much better in 2023 than last year. Here are three to put on your April must-buy list. 
Via InvestorPlace
FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle
The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.